Austar Lifesciences Limited AULSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 230.42M | 221.48M | 213.23M | 207.53M | 202.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 230.42M | 221.48M | 213.23M | 207.53M | 202.68M |
| Cost of Revenue | 188.65M | 180.25M | 172.41M | 166.75M | 161.78M |
| Gross Profit | 41.76M | 41.23M | 40.82M | 40.78M | 40.90M |
| SG&A Expenses | 32.27M | 31.54M | 30.92M | 31.89M | 32.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -3.12M | -2.74M | -2.38M | -2.92M | -3.47M |
| Total Operating Expenses | 224.35M | 215.46M | 207.24M | 202.07M | 197.75M |
| Operating Income | 6.06M | 6.02M | 6.00M | 5.45M | 4.93M |
| Income Before Tax | 5.08M | 5.87M | 6.68M | 6.26M | 5.85M |
| Income Tax Expenses | 2.48M | 2.30M | 2.12M | 1.70M | 1.29M |
| Earnings from Continuing Operations | 2.59 | 3.57 | 4.56 | 4.56 | 4.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -122.00K | 2.80K | 126.50K | 215.80K | 305.10K |
| Net Income | 2.47M | 3.58M | 4.68M | 4.77M | 4.87M |
| EBIT | 6.06M | 6.02M | 6.00M | 5.45M | 4.93M |
| EBITDA | 10.43M | 10.28M | 10.17M | 9.68M | 9.23M |
| EPS Basic | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| EPS Diluted | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Average Basic Shares Outstanding | 2.05B | 2.05B | 2.05B | 2.05B | 2.05B |
| Average Diluted Shares Outstanding | 2.05B | 2.05B | 2.05B | 2.05B | 2.05B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |